Dana Angelini, MD
Hematology & Oncology · Cleveland, OHNPI 1114160462
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,066 of the $13,569 with a category attached, or 96.3%. 6 manufacturers reported payments, led by Sanofi at 40.6% of the total. 2025 is the largest year on record at $6,915, 2.5 times the $2,740 reported in 2020.
Across 14 payments — averaging $969.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- Janssen Scientific Affairs, LLC$4K
- Janssen Global Services, LLC$3K
- Janssen Research & Development, LLC$1K
- Pharmacosmos Therapeutics Inc.$275
- Incyte Corporation$90
Across 2 payments — averaging $6255.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$13K
What the payments were for
- Consulting fees$13,06696%
- Food & beverage$5034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $5,514 |
| Janssen Scientific Affairs, LLC | 3 | $3,885 |
| Janssen Global Services, LLC | 1 | $2,725 |
| Janssen Research & Development, LLC | 1 | $1,080 |
| Pharmacosmos Therapeutics Inc. | 3 | $275 |
| Incyte Corporation | 1 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABLIVI$2,740
- COSELA$136
- Monoferric$109
How this compares
$13,569 in reported general payments places this provider in the 75th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $97,065 |
| XareltoRivaroxaban | 100 | $85,480 |
| Enoxaparin Sodium | 27 | $11,082 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 24 | $4,505 |
| Hydroxyurea | 46 | $1,058 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $563 |
| Pantoprazole Sodium | 15 | $133 |
| Prednisone | 15 | $80 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.